Bruker (NASDAQ:BRKR) Rating Increased to Strong-Buy at Rothschild Redb

Rothschild Redb upgraded Bruker (NASDAQ:BRKR) to a "strong-buy" rating. Other analysts have varied ratings, with a consensus of "Moderate Buy" and a target price of $50.25. Bruker's stock opened at $43.84, with a market cap of $6.66 billion. Recent insider sales and hedge fund activities are noted. Bruker's quarterly earnings exceeded expectations, with a revenue of $860.50 million.

Bruker (NASDAQ:BRKR - Get Free Report) was upgraded by stock analysts at Rothschild Redb to a "strong-buy" rating in a research note issued on Thursday,Zacks.com reports.

BRKR has been the topic of several other research reports. Redburn Partners set a $60.00 price target on shares of Bruker in a research report on Thursday. Citigroup reduced their price objective on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating for the company in a research note on Monday, August 4th. Jefferies Financial Group set a $60.00 target price on Bruker and gave the stock a "buy" rating in a research report on Monday, August 4th. TD Cowen lifted their price target on Bruker from $40.00 to $42.00 and gave the company a "hold" rating in a research report on Tuesday, November 4th. Finally, Rothschild & Co Redburn started coverage on Bruker in a report on Thursday. They set a "buy" rating and a $60.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $50.25.

Get Our Latest Stock Analysis on BRKR

Bruker Stock Performance

Shares of BRKR opened at $43.84 on Thursday. The firm has a market cap of $6.66 billion, a PE ratio of 84.31, a PEG ratio of 5.31 and a beta of 1.25. The stock's fifty day moving average price is $36.98 and its two-hundred day moving average price is $37.27. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. Bruker has a 1 year low of $28.53 and a 1 year high of $64.64.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.12. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The company had revenue of $860.50 million during the quarter, compared to the consensus estimate of $847.40 million. During the same quarter in the prior year, the company earned $0.60 EPS. The firm's quarterly revenue was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, equities research analysts forecast that Bruker will post 2.69 EPS for the current year.

Insider Buying and Selling at Bruker

In other news, Director Cynthia M. Friend sold 3,535 shares of Bruker stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the completion of the sale, the director owned 18,016 shares in the company, valued at approximately $581,016. This trade represents a 16.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John A. Ornell sold 6,233 shares of the company's stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total transaction of $243,087.00. Following the completion of the transaction, the director owned 35,212 shares in the company, valued at approximately $1,373,268. This trade represents a 15.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 27.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Bruker

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC raised its position in shares of Bruker by 377.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company's stock valued at $25,000 after buying an additional 487 shares in the last quarter. Huntington National Bank raised its position in Bruker by 750.0% during the second quarter. Huntington National Bank now owns 731 shares of the medical research company's stock valued at $30,000 after purchasing an additional 645 shares in the last quarter. Spire Wealth Management bought a new stake in Bruker during the second quarter worth about $32,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Bruker by 1,354.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company's stock worth $33,000 after purchasing an additional 745 shares in the last quarter. Finally, Parallel Advisors LLC increased its position in shares of Bruker by 63.0% during the 2nd quarter. Parallel Advisors LLC now owns 898 shares of the medical research company's stock valued at $37,000 after purchasing an additional 347 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.

About Bruker

(Get Free Report)

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Should You Invest $1,000 in Bruker Right Now?

Before you consider Bruker, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.

While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here